Name: Latest research reports of GlaxoSmithKline Pharmaceuticals Ltd. authored by Karvy and published by - Trendlyne research reports.
Item: GlaxoSmithKline Pharmaceuticals Ltd.
Rating: 1
Author: Karvy

GlaxoSmithKline Pharmaceuticals Ltd.

NSE: GLAXO | BSE: 500660 | ISIN: INE159A01016 | Industry: Pharmaceuticals
| Expensive Performer

2880.3500 43.45 (1.53%)

NSE Mar 28, 2025 15:31 PM

56.37% Gain from 52W Low

Volume: 108.2K

GlaxoSmithKline Pharmaceuticals Ltd.

19 May 2020

2880.35

1.53%

GlaxoSmithKline Pharmaceuticals Ltd-Results Update

Sell: GlaxoSmithKline Pharmaceut...

Target

Karvy

GlaxoSmithKline Pharmaceuticals Ltd: Outlook & Valuation: We downgrade our revenue estimates for FY21E by 4.3% to Rs 34.5 bn and introduce our revenues for FY22E.

GlaxoSmithKline Pharmaceuticals Ltd. has gained 26.64% in the last 3 Months

The Baseline | 28 Mar 2025, 05:07PM

Market closes lower, Jio Fin Serv invests Rs 1,000.2 crore in its subsidiary Jio Finance

Trendlyne Marketwatch | 28 Mar 2025, 04:05PM

Chart of the Week: Most new-age IT IPOs drop in valuations post listing

The Baseline | 27 Mar 2025